LeMaitre Vascular Inc (NASDAQ:LMAT) has received a consensus recommendation of “Hold” from the seven analysts that are covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $34.50.
A number of research firms recently issued reports on LMAT. Canaccord Genuity reissued a “hold” rating and issued a $33.00 price target on shares of LeMaitre Vascular in a research note on Friday, February 23rd. BidaskClub raised shares of LeMaitre Vascular from a “sell” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, Zacks Investment Research raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research note on Wednesday.
In other LeMaitre Vascular news, CEO George W. Lemaitre sold 5,700 shares of LeMaitre Vascular stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $35.56, for a total transaction of $202,692.00. Following the sale, the chief executive officer now owns 3,259,263 shares of the company’s stock, valued at approximately $115,899,392.28. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO George W. Lemaitre sold 42,036 shares of LeMaitre Vascular stock in a transaction on Monday, February 26th. The stock was sold at an average price of $35.68, for a total transaction of $1,499,844.48. Following the sale, the chief executive officer now directly owns 3,259,263 shares in the company, valued at approximately $116,290,503.84. The disclosure for this sale can be found here. Insiders own 23.70% of the company’s stock.
Shares of LeMaitre Vascular (NASDAQ:LMAT) opened at $34.76 on Thursday. LeMaitre Vascular has a one year low of $21.87 and a one year high of $39.88. The stock has a market cap of $648.99, a price-to-earnings ratio of 40.42, a P/E/G ratio of 2.44 and a beta of 0.53.
LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.01. LeMaitre Vascular had a net margin of 17.03% and a return on equity of 16.93%. The firm had revenue of $26.15 million for the quarter, compared to analysts’ expectations of $26.23 million. During the same quarter last year, the company earned $0.13 EPS. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. research analysts anticipate that LeMaitre Vascular will post 0.98 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 5th. Shareholders of record on Thursday, March 22nd will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.81%. The ex-dividend date of this dividend is Wednesday, March 21st. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.06. LeMaitre Vascular’s payout ratio is 25.58%.
COPYRIGHT VIOLATION WARNING: This story was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3229271/lemaitre-vascular-inc-lmat-given-consensus-rating-of-hold-by-brokerages.html.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.